App-Quantinova.ai

POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

Talia Golan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Olaparib

GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).

T.R. Jeffry Evans - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small bowel adenocarcinoma

N/A

A phase 3 study of first-line durvalumab (MEDI4736) tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.

Thomas Powles - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Ticilimumab

KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk nonmuscle-invasive bladder cancer (NMIBC).

Ashish M. Kamat - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Pembrolizumab

BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.

Thomas Powles - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Durvalumab

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.

James M. G. Larkin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Avelumab

ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.

Mark Stares - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Nivolumab

Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).

Emmanuel S. Antonarakis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Scott G. Williams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.

Howard M. Sandler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Bicalutamide

ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone-predominant metastatic castration-resistant prostate cancer.

Matthew R. Smith - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Alpharadin

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).

Ian D. Davis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL MCRPC): A Movember funded multicenter, randomized, controlled phase III study.

Fred Saad - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.

Stephanie Gaillard - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peritoneal cancer

Doxorubicin Hydrochloride

Avelumab (MSB0010718C; anti-PD-L1) pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase 3 JAVELIN Ovarian 200 trial.

Eric Pujade-Lauraine - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peritoneal cancer

Doxorubicin Hydrochloride

NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium.

Rosalind Margaret Glasspool - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear-cell adenocarcinoma

Doxorubicin Hydrochloride

TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Agnieszka Michael - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peritoneal cancer

MVA-5T4

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus either Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.

Thomas J. Herzog - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Doxorubicin Hydrochloride

WEE WIN: Window of opportunity study of induction Wee1 inhibition in advanced high-grade serous ovarian cancer.

Shannon Neville Westin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

AZD-1775

De-ESCALaTE: Comparison of early and late toxic events in low-risk HPV positive oropharyngeal carcinoma patients treated with chemoradiotherapy, cetuximab versus cisplatin.

Hisham Mohamed Mehanna - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Oropharyngeal carcinoma

Erbitux

Filters

45280 Abstracts